{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:15:50Z","timestamp":1791159350745,"version":"4.1.0"},"reference-count":7,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.pharma.2009.06.006","type":"journal-article","created":{"date-parts":[[2009,7,31]],"date-time":"2009-07-31T12:01:10Z","timestamp":1249041670000},"page":"299-303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Les traitements de substitution aux opiac\u00e9s\u00a0: bilan des politiques publiques"],"prefix":"10.1016","volume":"67","author":[{"given":"F.","family":"Chast","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.pharma.2009.06.006_bib1","first-page":"1177","article-title":"Efficacit\u00e9 des mesures prises en France pour r\u00e9duire les effets de la toxicomanie \u00e0 l\u2019h\u00e9ro\u00efne par voie veineuse","volume":"181","author":"Henrion","year":"1997","journal-title":"Bull Acad Natl Med"},{"key":"10.1016\/j.pharma.2009.06.006_bib2","unstructured":"Circulaire minist\u00e9rielle DGS\/SP 3\/95 no\u00a029 du 31.03.1995."},{"issue":"5","key":"10.1016\/j.pharma.2009.06.006_bib3","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s11920-007-0046-2","article-title":"Why buprenorphine is so successful in treating opiate addiction in France","volume":"9","author":"Fatseas","year":"2007","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.pharma.2009.06.006_bib4","unstructured":"Duburcq A, Charpak Y, Blin P, Madec L. Suivi \u00e0 deux ans d\u2019une cohorte de patients sous bupr\u00e9norphine haut dosage. R\u00e9sultats de l\u2019\u00e9tude suivi pharmaco-\u00e9pid\u00e9miologique du Subutex\u00ae en m\u00e9decine de ville (SPESUB)\u00a0; Revue d\u2019\u00e9pid\u00e9miologie et de sant\u00e9 publique (2000);48(4):363."},{"issue":"2","key":"10.1016\/j.pharma.2009.06.006_bib5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1046\/j.1360-0443.2001.96226710.x","article-title":"Injecting misuse of buprenorphine among French drug users","volume":"96","author":"Obadia","year":"2001","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.pharma.2009.06.006_bib6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/00139709-200625020-00002","article-title":"Does high-dose buprenorphine cause respiratory depression? Possible mechanisms and therapeutic consequences","volume":"25","author":"M\u00e9garbane","year":"2006","journal-title":"Toxicol Rev"},{"key":"10.1016\/j.pharma.2009.06.006_bib7","doi-asserted-by":"crossref","unstructured":"Bell JR, Butler B, Lawrance A, Batey R, Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend., Available online 13 May 2009.","DOI":"10.1016\/j.drugalcdep.2009.03.020"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450909000923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450909000923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:26:44Z","timestamp":1757719604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450909000923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":7,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S0003450909000923"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2009.06.006","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les traitements de substitution aux opiac\u00e9s\u00a0: bilan des politiques publiques","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2009.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}